Рассеянный склероз |
LDN терапия Я хочу обратить внимание всех тех, у кого не большой стаж заболевания рассеянным склерозом (РС) и не только их. Это касается всех, болеющих РС. LDN терапия - воздействие налтрексона гидрохлорида на область головного мозга. Уже лет 15 известно, что у больных РС снижен в крови уровень эндорфинов - натуральных опиатов, вырабатываемых собственным организмом, которые действуют в центральной нервной системе на рецепторы. Тогда, чтобы преодолеть возникший блок, организм начнет вырабатывать эндорфины в большем количестве. Именно таким механизмом действия обосновывается применение малых доз налтрексона (LDN) при РС. Основная суть самой терапии - прием 3 мг лекарства в течение месяца, а затем переход на 4,5 мг. Принимаете один месяц по 3 мг, и потом неделю по 4,5мг, а затем неделя перерыв. В дальнейшем принимаете по 4,5 мг. И так на протяжении не ограничнного времени по необходимости. Через 2-3 месяца Вы сами поймете надо ли продолжать прием или нет. Есть и другие варианты: 10 дней принимают по 3 мг, а затем пару дней перерыв. Варианты определяются опытным путем индивидуально. Если чувствуете, что действие лекарства прекратилось или ослабло, то необходимо сделать перерыв. Перерыв определяется опытным путем. Долгий прием - большой перерыв, короткий (неделя или немного более) - короткий перерыв. Возможно, прием надо проводить пожизненно. Если, конечно, есть эффект. В Америке имеются больные, которые его принимают уже более 17 лет и без обострений. Об этой терапии я узнал совсем недавно и подключился к ней. Пока мне еще рано говорить о каких-то положительных результатах. Да это и не имеет большого смысла, так как заболевание очень индивидуально. И кому-то оно поможет, а кому-то нет. Основной результат от LDN терапии это ослабление некоторых симптомов заболевания и, что самое главное, его стабилизация. Остановка дальнейшего развития заболевания. Хочу отметить сранительно малую стоиость терапии. Давайте прикинем стоимость терапии LDN. В среднем стоимость одной капсулы (таблетки), в которой содержится 50 мг гидрохлорида налтрексона составляет около 90 руб. Вы ее растворяете в 50 мл дистиллированной воды и принимаете по 3 мл раствора (т.е. по 3 мг гидрохлорида налтрексона) в день. Получается, что вам одной капсулы достаточно на 50/3=16(приблизительно) дней. Ггрубо говоря, 2 капсулы в месяц, или в деньгах 90*2=180 руб. в месяц. Мне кажется, что это сравнительно не дорого. Мне это лекарство (Антаксон) обошлось в 900 руб. Одна упаковка в 10 капсул. И по моим расчетам его должно мне хватить на 4-4,5 месяца. Лекарства, содержащие гидрохлорид налтрексона - Антаксон капс 50мг бл N10x1 Италия; Налтрексон ФВ капс 50мг бл N10x1 Россия; Ревиа тб 50мг фл N30x1 США. Хочу обратить внимание на количество основного лекарственного вещества - 50 мг. Дело в том, что фармацевтическая промышленность выпускает лекарство и в меньших дозах, но можно нарваться на приобретение не работающего средства. Теперь я поделюсь опытом приготовления данного средства. Берете одну капсулу, ножницами срезаете ее верхушку и высыпаете содержимое в не большую стеклянную банку. Затем туда добавляете 50 мл дистиллированной воды. Все. Средство готово. Принимаете по 3 мл в день прерорально, т.е. в рот. Время приема с 21.00 по 3.00. Банку храните в холодильнике. Для удобства приготовления и приема лекарства используйте шприцы на 20 мл и 5 мл Сравнительно низкая цена играет негативную роль. Фармацевтические фирмы отказываются провести медицинское исследование данного средства при заболевании рассеянный склероз. Само лекарство известно давно и применяется для лечения наркомании и алкоголизма. Фирмам не выгодно вкладывать деньги в серьезные исследования. Единственное, я могу привести две статьи и интервью с американским врачем, который занимается изучением данного средства применительно к болезни рассеянный склероз. Статьи (есть квалифицированный перевод) и интервью на английском языке. 1-ая
статья. О
том, как
правильно
входить в LDN
терапию. Перевод Low-dose Naltrexone in the Treatment of Multiple Sclerosis These notes are important. It is essential that you read and thoroughly understand them before starting the low-dose naltrexone (LDN) treatment. LDN is a treatment method that has been in use in the USA since 1985 but is relatively new in this country. Despite its claimed successful use in America, until fully proved here, it must be considered as experimental and that no beneficial response can be guaranteed. In addition, despite the fact that the drug is at a very low dose, the absence of significant introductory or prolonged side-effects cannot be excluded. The treatment can only be provided if these conditions are accepted. Naltrexone is a drug, referred to as an opiate antagonist. Its normal use is to treat opiate drug addicts addicted to such as heroin or morphine. Doses used for this purpose is usually 150 mg or more each day. This method was devised, and has since been developed, by Dr Bernard Bihari, a practicing neuro-physician in New York, USA. Dr Bihari is qualified in Internal Medicine, Psychiatry and Neurology. His address is 29w 15th Street, New York, New York; telephone number: 212 929 4190. His website is <http://www.lowdosenaltrexone.com>www.lowdosenaltrexone.com <http://www.lowdosenaltrexone.com> The method was first put to use, in the treatment of MS, in 1985. It has since been reported that those receiving this drug in the treatment of MS, initially at a dose of just 3 mg per day, have experienced a range of improvements, including such as: reduced spasm and fatigue, improved bladder control, improved heat tolerance, with improvements in mobility, sleep, pain, tremor and other symptoms. The two main symptoms that appear to improve most significantly are muscle spasm and fatigue. The current maximum recommended dose is 4.5 mg per day, taken after 9 pm at night. The introductory dose however, remains at just 3 mg for the first month of treatment. After this period, in the absence of any introductory side-effects, and for greater therapeutic response, the dose may be increased to 4.5 mg/ day if desired. How Naltrexone Works: The benefits of this drug are apparently due to the temporary inhibition of brain endorphins (a natural pain-killer, produced in the brain). This results in a reactive increase in the production of endorphins, which would expectedly result in a reduction in painful symptoms and an increase in the sense of wellbeing. In addition, increased levels of endorphins would also be expected to stimulate the immune system, promoting an overall increase in the numbers of T lymphocytes. This effect has been observed in Dr Bihari's research. This increase in T-cell numbers apparently restores a more normal balance of the T-cells such that the effects of the disease process is reduced. Thus, it has been observed that, in those suffering the relapsing- remitting form of MS, the number of relapses is reduced, and the rate of progression of the disease is diminished. In fact, Dr Bihari's research suggests that no-one receiving this treatment as a regular therapy, has experienced a relapse while actually on the treatment. Occasionally however, there may be a short-term increase in symptoms during, for example, periods of infection or stress, arising from previously active lesions already present in the brain or spinal cord. In chronic, progressive MS (either primary or secondary) there appears to be a similar reduction in the progression of disease symptoms. It must also be emphasised that a positive beneficial response to this treatment cannot be assured or guaranteed. Side-Effects: When starting this therapy in the treatment of MS, the possibility of adverse side-effects due to the drug, cannot be entirely excluded. The likelihood of damaging side-effects is believed to be minimal however, as the drug is used at such a low dose. Reversible liver damage has been found to occur only in those receiving doses greater than 300 mg per day. Due to the possible toxic effects of this drug upon the liver it is required that anyone previously suffering liver or kidney problems should report this condition before starting therapy. Due to the extremely low dose of the drug however, this risk is believed to be minimal. In addition, there may also be some initial transient, though temporary, increase in MS symptoms. Experience in using this method has demonstrated most commonly, such as disturbed sleep, occasionally with vivid, bizarre and disturbing dreams, tiredness, fatigue, spasm and pain. These increased symptoms usually fade and disappear within five to seven days. Rarely, other transient symptoms have included more severe pain and spasm, headache, diarrhea or vomiting. These additional symptoms would appear to be associated with the previous frequent use of strong analgesics, which effectively create an addiction and dependency, thus increasing the body's sensitivity to pain. It has also recently become apparent that some patients have experienced additional symptoms, such as muscle stiffness or pain, after a few weeks of therapy. This is believed to be due to an occasional increased sensitivity to the lactose filler used in the capsules. If this should occur, a similar preparation, using calcium carbonate filler, may be provided as an alternative. The early but temporary increase in symptoms may also perhaps be explained when we consider the manner in which this drug is expected to work. Initially, MS occurs due to a reduction in the activity of the controlling influence of the suppressor T-cells within the immune system. During an acute relapse, the overall number of T-cells is reduced, the normal balance of helper T-cells and suppressor T-cells is disrupted and the damaging helper (CD-4) T-cells tend to predominate. This is the situation most pronounced during an acute relapse but occurs similarly, but to a lesser extent, in chronic progressive MS. Under the influence of LDN there will be an expected increase in the overall numbers of T-cells but, because the CD-4, helper T-cells tend to predominate at this time, an increase in their numbers will expectedly tend to increase MS symptoms. It is only when the numbers of suppressor T-cells effectively "catch up" that the normal balance is restored and symptoms once again diminish and improve. Contraindications and Special Precautions: In addition, because LDN stimulates the immune system and many of the drugs routinely used by the NHS in the treatment of MS further suppress the immune system, LDN cannot be used in company with steroids, beta interferon, methotrexate, azathioprine or mitozantrone or any other immune suppressant drug. If there is any doubt, please submit a full list of the drugs you are presently taking so that their compatibility may be assessed. In addition, because LDN will also block the analgesic effects of any opiate drugs (includes codeine, dihydrocodeine, tramadol, morphine, pethidine or diamorphine) presently being taken, the use of LDN will initially greatly increase the level of pain experienced. It is therefore advisable that any opiate-like drugs be discontinued at least two weeks before this treatment is initiated. Intermittent Therapy: When a drug is used for a prolonged period of treatment, even at the very low dose as used in this circumstance, it remains possible that the body will slowly adjust to the continuous presence of the drug, when the response to that drug will eventually diminish. This process is referred to as accommodation. In addition, as a result of this process of accommodation, continuous use of a drug will also create a situation of dependency. In this circumstance, what was previously considered to be a normal state of physiological activity (in this case, the level of brain endorphins produced) will become dependent upon the continuing presence of the drug. To prevent this situation developing, and contrary to the advice suggested by Dr Bihari, it is considered advisable to use a form of intermittent therapy. The suggested routine is to take the naltrexone each day for three weeks, after which treatment is stopped for one week. This pattern of intermittent use will allow the body, during the non- treatment period, to readjust back to a normal state of activity so that when the drug is reintroduced once again, it will have a renewed and enhanced effect, thus maintaining the therapeutic benefits. Thus, after the introductory first month of treatment at 3 mg, take one week of the 4.5 mg capsules to establish the level of response at this dose. It would then be appropriate to stop treatment for one week, after which therapy is continued with three weeks on and one week off in a regular repeating pattern of use. It is anticipated that this method of use will reduce the risk of MS relapse following temporary or prolonged withdrawal of the drug for whatever reason. This method has been tested with no apparent increase in MS symptoms during the period of non-treatment. When starting the treatment it is essential that any untoward or adverse side-effects are reported immediately so that the treatment process can be further assessed and, if necessary, modified. 2-ая статья. MS experimental drug `could save state millions of euro' ИнтервьюИз которого проясняется механизм воздействия. I found this on Goodshape's site http://goodshape.net/LDN.html Вы можете также поделиться своими методами борьбы с болезнью, а также высказать Ваши мысли и мнение, приняв участие в нашем ФОРУМЕ |